In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


For Shire, Life After Adderall XR? Yes

Executive Summary

Shire has scaled its Adderall XR patent cliff, replenishing lost blockbuster sales with revenues from niche products, smart life-cycle management, and some good-old-fashioned luck. IN VIVO interviews CEO Angus Russell.

You may also be interested in...

Shire CEO Angus Russell On The Value Proposition For Drugs

Since 2008, Shire PLC 's market cap has nearly doubled ($8.3 billion to $16 billion) and its employee count has grown from 1,600 to roughly 4,300. Analysts say the U.K. company is on track to deliver its revenue guidance of 15% compound annual growth rate (CAGR) through 2015 – far above the expected anemic performance of most pharmaceutical companies.

Sanofi And Genzyme: Do Big Pharmas And Orphan Drugs Fit Together?

Big pharmas from Pfizer to GlaxoSmithKline are expanding their initiatives in niche disease areas, but if Sanofi-Aventis acquires Genzyme as it hopes, the French drug maker could soon emerge as an orphan drug leader

Sanofi And Genzyme: Do Big Pharmas And Orphan Drugs Fit Together?

If successful, Sanofi-Aventis' attempt to acquire Genzyme would catapult the company into the orphan drug business, marking Big Pharma's most aggressive strategy in the space to date.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts